1-3 of 3
Christine Pivot
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results

Franck E. Nicolini, MD PhD, Gabriel Etienne, MD PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, MD, Laurence Legros, MD, Stéphane Giraudier, MD PhD, Valérie Coiteux, MD, Agnes Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, Shanti Amé, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD PhD, Marie-Claude Gagnieu, PharmD, PhD, Stéphane Morisset, Stat, Christine Pivot, PharmD, Madeleine Etienne, CRA, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 1578.
https://doi.org/10.1182/blood.V126.23.1578.1578
Published: 2015
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

Erythropoietin Use In Patients with AML or Undergoing Allogeneic HSCT Significantly Improves Quality of Life and Reduces Red Blood Cells and Platelets Transfusions without Any Survival Effect.

Mauricette Michallet, Karine Goldet, CRA, Stephane Morisset, Stat., Mohamad Sobh, Pharm., M., Youcef Chelghoum, MD, Xavier Thomas, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jean Vial, Catherine Renzullo, Pharm., Carole Paillet, Pharm., Christine Pivot, Pharm., Perrine Badol-Van Straaten, Angelique Denis, Anne Termoz, Franck E Nicolini, MD, PhD, Isabelle Jaisson-Hot
Journal: Blood
Blood (2010) 116 (21): 3810.
https://doi.org/10.1182/blood.V116.21.3810.3810
Published: 2010